KBY Biotech Indexv0.0.34
Search
← Pipeline|ASP-8596

ASP-8596

Phase 2
By Aspen Global
Source: Trial-derived·Trials: 1
Modality
Cell Therapy
MOA
CAR-T CD19
Target
CD123
Pathway
RNA Splicing
Rett
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
Oct 2017
→ Jan 2029
Phase 2Current
NCT05425786
1,104 pts·Rett
2017-10→2029-01·Recruiting
1,104 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-022.8y awayPh2 Data· Rett
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2
Recruit…
Catalysts
Ph2 Data
2029-01-02 · 2.8y away
Rett
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05425786Phase 2RettRecruiting1104PFS
Competitors (10)
DrugCompanyPhaseTargetMOA
RHH-1546RochePhase 2/3C5CAR-T CD19
DatoglumideAbbVieApprovedCFTRCAR-T CD19
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
REG-7737RegeneronPreclinicalCD123WRNi
BII-4342BiogenPhase 2/3CGRPCAR-T CD19
TalasotorasibExelixisPreclinicalAPOC3CAR-T CD19
IvotuximabMadrigal PharmaPhase 2CD123CFTRmod
ElracapivasertibKymeraPhase 3PRMT5CAR-T CD19
SND-4562SyndaxNDA/BLAAuroraACAR-T CD19
ZorizumabBeamApprovedCD123AuroraAi